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Purpose or Objective: Anal cancers are treated by definitive 
chemoradiotherapy of the primary tumor and pelvic nodes. 
Although survival is high (5y 75%), locoregional recurrence 
occurs in 24% of patients. Patients are mostly treated with 
IMRT and VMAT, and therefore precise dose delivery is 
important. For target volume delineation typically either PET 
or MRI is used together with planning CT, but practice varies 
between institutions. In the current work, we aim to 
investigate the variability between imaging modalities and 
oncologists with respect to target volume delineation based 
on either PET/CT or MRI/CT information. 
 
Material and Methods: Twenty patients with anal cancer 
referred to chemoradiotherapy were prospectively included. 
Written informed consent was obtained from all patients and 
the regional ethics committee approved the study. Prior to 
therapy, patients underwent a planning CT scan, a PET/CT 
scan with 18FDG and T2 and diffusion weighted MRI scans at a 
3T scanner. At the treatment planning station (Varian 
Eclipse), all images where co-registered to the planning CT 
scan. Three oncologists delineated the Gross tumor volume 
(GTV) independently of each other twice for each patient, 
once with medical records and images blinded for MRI 
information, and once blinded for PET information. The CT 
image information was always available. A randomization 
scheme of the order of the anonymized patients was used 
during delineation to minimize intra-observer bias. All 
volumes were exported from the treatment planning system, 
analyzed by calculating the DICE coefficients and compared 
with the Wilcoxon Signed-rank test. 
 
Results: The median volume of the GTV was respectively 
27.5 cm3 and 31.0 cm3 for PET and MRI, and there was a high 
correlation (r=0.94) between the volumes. The DICE 
coefficient (minimum, median, maximum) was 0.43, 0.81, 
0.93 and 0.50, 0.75, 0.89 for PET and MRI. These DICE 
distributions were significantly different (P=0.03). Half of the 
patients with low DICE (<0.7) for PET, also gave low DICE for 
MRI, this indicated difficulties with delineation irrespective 
of imaging modality. For inter-modality comparison (PET to 
MRI for same observer), the DICE coefficient was 0.31, 0.75, 
0.92, with a significant difference in distribution relative to 
the inter-observer distribution. 
 
 
Conclusion: PET and MRI produced similar GTV volumes for 
radiotherapy planning of anal cancer. However, PET has a 
significantly lower inter-observer variability in terms of the 
DICE coefficients. Still, the deviations between PET and MRI 
were not substantial and may not translate into clinically 
meaningful differences. This is also supported by the 
relatively high inter-modality DICE coefficients. Thus, 
radiotherapy target delineation for anal cancer is performed 
quite consistently among observers and is not strongly 
dependent on whether PET or MRI is used. 
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Purpose or Objective: In locally advanced rectal cancer 
(LARC), further advances in individualised treatment 
approaches require identification of robust biomarkers. 
Although metabolic reprogramming has been regarded 
essential for cancer cell proliferation, the systematic 
characterisation of activated metabolic pathways in 
aggressive cancer is scarce. Hence, by recognising the link 
between altered tumour metabolism and disease 
aggressiveness, we aimed to identify associations between 
pretreatment tumour metabolic profiles and therapeutic 
outcome in LARC. 
 
Material and Methods: Tumour metabolic profiles were 
acquired from 54 LARC patients, receiving induction 
neoadjuvant chemotherapy followed by long-course 
chemoradiotherapy and surgery, by using high-resolution 
magic angle spinning magnetic resonance spectroscopy. 
Metabolite concentrations were correlated to TNM and 
presence of disseminated tumour cells (DTC) at time of 
diagnosis, and to ypTN and tumour regression grade (TRG) 
following the neodjuvant treatment. All patients had either 
reached 5 years of follow-up or were scored with a 
progression-free survival (PFS) event at time of analysis. The 
performance of metabolite concentrations in prediction of 
PFS was assessed by receiver operating characteristic curves. 
Univariate Cox regression assessed associations between 
selected variables and PFS; those being significant were 
entered into multivariate analysis. Survival differences were 
assessed by the Kaplan-Meier method. 
 
Results: Pretreatment tumour metabolite concentrations 
showed no significant associations to TNM, DTC, ypTN or TRG. 
In univariate regression analysis, high concentrations of 
glycine, creatine and myo-inositol were significantly 
associated to poor PFS, with distant metastasis to the lung 
and/or liver being the main PFS event (87.5% of events). 
When separating patients above and below the identified cut-
off concentrations the respective estimated 5-year PFS were 
85% and 50% for glycine, 74% and 29% for creatine and 81% 
and 50% for myo-inositol. In multivariate analysis, high 
glycine concentration remained most significantly associated 
to poor PFS (hazard ratio = 4.4, 95% confidence interval = 
1.4–14.3, p = 0.008). 
 
Conclusion: High tumour glycine concentration was 
identified as adverse prognostic factor for PFS in LARC. In a 
patient population treated with curative intent but with 
metastatic disease as main PFS event these results motivate 
further investigations of glycine as early predictor of 
metastatic progression and as potential therapeutic target. 
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Purpose or Objective: The prophylactic inguinal lymph-
nodes (LNs) radiotherapy (RT) is considered the standard 
treatment, however it implies more toxicity. Moreover, 
inguinal recurrence occurs in 0%-12% of T1-T2, and 19%-30% 
of T3-T4 patients (pts) who did not receive prophylactic 
inguinal RT. So, 70%-81% of T3-T4 pts are uselessly irradiated, 
and 0%-12% of T1-T2 pts should be treated. An improvement 
of staging is mandatory. Aim of this study is to evaluate the 
role of sentinel lymph-node biopsy (SLNB) in staging and 
treatment of pts with anal cancer.  
 
Material and Methods: Patients with squamous cell 
carcinoma of anal canal were staged with physical 
examination, endoscopy, chest and abdomen CT, pelvic MR, 
and simulation FDG-PET. Pts without gross inguinal LN 
metastasis were candidate for the lymphoscintigraphy with 
99mTC nanocolloid. The CTV included the GTV (primary 
tumour and positive LNs), mesorectum, internal and common 
iliac LNs. As the inguinal RT was considered standard, the 
radiation oncologists were left free to decide whether 
irradiate this region independently from the clinical stage 
and the SLNB histological results. PTV1 and PTV2 
corresponded to GTV and CTV, respectively, with a margin of 
0.5 cm. Prescribed dose was 50.4Gy in 28 F to the PTV2, and 
64.8Gy in 36 F, as sequential boost, to the PTV1. IMRT or 
Volumetric Modulated Arc Therapy (VMAT) were used. 
Concomitant chemotherapy consisted of 2 cycles of Mito-C 10 
mg/m2, and continuous infusion 5-FU 1000 mg/m2/day for 4 
consecutive days.  
 
Results: From 3/2008 to 2/2014, 48 consecutive pts were 
treated (T1=9, T2=15, T3=16, T4=8). PET was performed in 42 
out of the 48 pts, and 27 out of these 42 pts underwent 
lymphoscintigraphy. Pathologic inguinal uptake was shown in 
15/42 (36%) pts. Lymphoscigraphy was performed in 9 out of 
these 15 pts. Histological examination was performed in 8 pts 
(SLN not found in 1 pt) and confirmed inguinal metastasis in 
3/8 pts (37.5% ) but did not confirmed metastasis in 5 pts 
(62.5%). PET did not show pathologic uptake in 27/42 pts 
(64%). Lymphoscintigraphy was performed in 18 out of these 
27 pts: SLN was not found in 1 pt. Histological examination 
found metastasis in 2/17 (12%) and confirmed the absence of 
metastasis in 15 pts (88%). Thirty-one pts received 
prophylactic or curative RT to the groins, the “Groin group”, 
and 17 pts did not , the “No groin group”. All the 17 pts of 
the “No groin group” underwent SLNB procedure: 16 pts had 
SLNB histologically negative, 1 pt had lymphoscintigraphy 
negative (SLN not found ) and PET negative; two pts with PET 
positive in right inguinal LN but ipsilateral SLNB negative 
were not irradiated. No pt in both groups had inguinal relapse 
or progression. Of note, median follow up duration in the “No 
groin group” was 41 months (19.2-90.7 months). 
 
Conclusion: SLNB can further improve the PET based staging 
and select the “true negative” patients for which the inguinal 
LN irradiation could be avoided. 
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Purpose or Objective: to evaluate efficacy and tolerability 
of stereotactic ablative radiotherapy (SABR) in the treatment 
of patients with colorectal cancer with exclusive 
oligometastases to the lung. 
 
Material and Methods: we treated 62 lung metastases in 38 
patients with oligometastatic colorectal cancer. Inclusion 
criteria were: primary tumor controlled, ≤ 5 lung metastases, 
no other active sites of disease at the time of the SABR. Dose 
prescription was: 23Gy/1 fr per central lesion <30 cc (18 
lesions), 30Gy/1fr for peripheral metastases <30 cc (35 
lesions), 45Gy/3fr for peripheral lesion >30cc (9 lesions). 
Twenty patients had 1 metastasis (53%), 14 patients had 2 
metastases (37%)and 4 patients tree-to-four metastases 
(10%). Median BED was 120 Gy. OS, PFS, MFS, local control 
and toxicity were evaluated. 
 
Results: median follow-up was 24 months (ranged 3-76 mo). 
Median actuarial survival was 34 months (c.i. 20-47 months). 
Overall survival (OS) at 1-, 2- and 5-years was 80%, 50.7% and 
26.9% respectively. Complete response (CR) was achieved in 
22/62 lesions (35.4%). Median disease-free survival (DFS) was 
24 months (ranged 13-34 months). DFS at 1-, 2- and 5-years 
was 79.8% and 40.4% and 22%, respectively. Complete 
response (CR) was the only prognostic factor significantly 
correlated with OS, PFS and metastasis-free survival (MFS) 
(p= 0.001 in each case). Patients with CR had 1-,2- and 5-
years OS of 100%, 90.9% and 67.3%, while patients with 
partial response (PR) and stable disease (SD) had respectively 
69.2, 34.6% and 0% and 63.5% at 1 and 2-years and 15.9% at 
5-years. Acute G1-2 lung toxicity, according to the CTCAE-
V4.0, was 10%, G3 lung toxicity was 1.6%. Late G1-2 toxicity 
rate was 25%. No late G3 toxicity was found. 
 
Conclusion: SABR has a high rate of local control in the lung 
metastasis from colorectal cancer and also affect survival. CR 
statistically correlated with OS, PFS and MFS, even at long-
term. There is a need of prospective trials to confirm these 
data and to identify the right selection criteria and the best 
timing with systemic therapies. 
 
Poster: Clinical track: Gynaecological (endometrium, 
cervix, vagina, vulva)  
 
 
PO-0723  
Short time interval between radiation and hyperthermia 
improves treatment outcome in cervical cancer 
C.M. Van Leeuwen
1Academic Medical Center, Radiation Oncology, Amsterdam, 
The Netherlands 
1, A.L. Oei1, K.W.T.K. Chin1, L.J.A. 
Stalpers1, A. Bel1, J. Crezee1, N.A.P. Franken1, H.P. Kok1 
 
Purpose or Objective: To determine the effect of the time 
interval between external beam radiotherapy (EBRT) and 
hyperthermia (HT) treatments on locoregional recurrence and 
overall survival of patients with cervical cancer. 
 
Material and Methods: This retrospective study included 59 
women with locally advanced (stage IB2-IVA) cervical cancer, 
all treated with radiotherapy and HT. Additional treatment 
with chemotherapy was reason for exclusion. 
Patients received four to five weekly HT treatments 
concurrent with 23-28 fractions (1.8-2.0 Gy) EBRT and a 
brachytherapy boost (20-24Gy). On HT treatment days, HT 
was given after EBRT. The mean time interval between the 
EBRT and HT treatments that were delivered on the same day 
was used to characterize the typical time interval for that 
patient. The median thereof (79.2 minutes) was used to split 
the cohort in a ‘short’ and ‘long’ time-interval group. Median 
time intervals were 65.8 minutes (range 33.8-79.2) and 91.7 
minutes (range 80.0-125.2) for the short and long time-
interval group, respectively.  
Locoregional recurrence and overall survival were estimated 
using Kaplan-Meier analysis, and compared by a log-rank test. 
To correct for any potential confounding factors, a stepwise 
Cox regression analysis using backward elimination was used 
with time-interval group, age, FIGO stage, number of HT 
treatments, tumour temperature during HT treatment (T90), 
lymph node status and smoking as covariates. 
